Investigation Report on China Megestrol Market, 2010-2019

Nowadays, breast cancer has the highest incidence among malignancy for women all over the world. According to the statistics released by World Health Organization (WHO), …
Reference: 1505185
Price: $2,000.00
Tax included

General

Publisher:
CRI
Geography Covered
China
Publication Date
5/28/2015
Pages
30
Version:
2010
Charts:
30
Language
  • English
  • Chinese
Format
License

Description

Nowadays, breast cancer has the highest incidence among malignancy for women all over the world. According to the statistics released by World Health Organization (WHO), the number of breast cancer cases around the world reaches 1.2 million per year while a global death toll is about 0.5 million per year. In the past decade, the annual growth rate of the incidence of breast cancer hit 8%. By 2020, the incidence of cancer will increase by 50% and the number of new cases of cancer around the world will reach 15 million per year.
In recent years, the growth rate of the incidence of breast cancer in China ranks first in the world with one in ten women suffering from breast cancer. In 2015, the number of new cases of breast cancer in China has surpassed that of the US and become the largest in the world. In 2014, the number of newly confirmed cases of breast cancer was 0.225 million, increasing sharply by 50% compared with 2004. At the same time, nearly two thirds of newly confirmed cases can survive for more than 20 years with a long-term survival rate rising sharply by 20%. According to WTO, this astonishing progress benefits from the discovery and sale of new drugs with better efficacy and fewer adverse reactions.
About two thirds of breast cancer patients use hormone therapy. Common varieties of progestin are medroxyprogesterone and megestrol which act by blocking the source of human estrogen with an unsatisfactory efficacy rate of 30%-50%. Since their efficacy is not better than other drugs for breast cancer and their price is relatively high, their sales is not very big. But according to the latest domestic reports, progestin occupies nearly 2% of clinical medication for breast cancer with rising sales. After entering Chinese market, Megestrol develops very fast. Although its sales in 2011 underwent a small decline, it still enjoys an obvious growth trend in recent years. The annual sales of megestrol rose from CNY 29.95 million in 2010 to CNY 37.22 million in 2014 with a compound growth rate of 5.58%.

Readers can get at least the following information through this report:
-market size of megestrol in China
-major manufacturers of megestrol for Chinese market and their market share
-retail price of megestrol in Chinese market
-market outlook of megestrol in China

The author suggests the following groups of people purchase this report:
-manufacturers of progestin
-investors/ research institutions interested in Chinese medicine market
-any interest in medicine market in China, please contact CRI for customized survey service
Table of Contents
1 Related Concepts of Megestrol
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Megestrol in China
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Megestrol in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Manufacturers of Megestrol in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Dosage Forms of Megestrol in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Price of Megestrol in Chinese Hospitals in 2014
6.1 Shanghai Sine Tianping Pharmaceutical Co., Ltd (Trade Name: Que Nuo)
6.2 Guccess (Trade Name: JIADI)
6.3 Gerui Pharmaceutical Company (Trade Name: Yi Li Zhi)
6.4 Zhejiang Wanlian Pharmaceutical Co., Ltd (Trade Name: Mi TuoSuo)
6.5 Deten Pharmaceutical (Trade Name: Ai Nuo Ke)

7 Major Manufacturers of Megestrol for Chinese Market, 2010-2014
7.1 Gerui Pharmaceutical Company
7.2 Guccess
7.3 Shanghai Sine Tianping Pharmaceutical Co., Ltd
7.4 Deten Pharmaceutical
7.5 Zhejiang Wanlian Pharmaceutical Co., Ltd

8 Market Outlook of Megestrol in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

Selected Charts
Chart Drug Registration Information of Megestrol in China
Chart Sales Status of Megestrol in Chinese Market, 2010-2014
Chart Sales Value of Megestrol in China, 2010-2014
Chart Sales Value of Megestrol by Regions in China, 2010-2014
Chart Sales Volume of Megestrol in China, 2010-2014 (unit: million)
Chart Sales Value and Market Share of TOP5 Manufacturers of Megestrol in Chinese Market, 2010-2014
Chart Sales Value and Market Share of Megestrol Made by Gerui, 2010-2014
Chart Sales Value and Market Share of Megestrol Made by Deten, 2010-2014
Chart Market Share of TOP5 Manufacturers of Megestrol by Sales Value in Chinese Market, 2010-2014
Chart Sales Volume and Market Share of Megestrol Made by Shanghai Sine Tianping, 2010-2014
Chart Sales Value and Market Share of Megestrol Tablets in China, 2010-2014
Chart Price of Megestrol Made by Shanghai Sine Tianping Pharmaceutical Co., Ltd in Some Cities in China, 2014
Chart Price of Megestrol Made by Guccess in Some Cities in China, 2014
Chart Price of Megestrol Made by Deten Pharmaceutical in Some Cities in China, 2014
Scroll